Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

• DOI: 10.1038/s41467-021-20973-3
• Publication Date: 2021-02-20T16:02:53Z
• Authors: Matthias Becker; Monika Strengert; Daniel Junker; Philipp D. Kaiser; Tobias Kerrinnes; Bjoern Traenkle; Heiko Dinter; Julia Häring; Stéphane Ghozzi; Anne Zeck; Frank Weise; Andreas Peter; Sebastian Hörber; Simon Fink; Felix Ruoff; Alex Dulovic; Tamam Bakchoul; Armin Baillot; Stefan Lohse; Markus Cornberg; Thomas Illig; Jens Gottlieb; Sigrun Smola; André Karch; Klaus Berger; Hans-Georg Rammensee; Katja Schenke-Lay...; Annika Nelde; Melanie Märklin; Jonas S. Heitmann; Juliane S. Walz; Markus Templin; Thomas O. Joos; Ulrich Rothbauer; Gérard Krause; Nicole Schneiderh...
• Keywords: Multiplex; Seroconversion; Coronavirus; Pandemic; Cross-reactivity

Abstract The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis required understand the manifestation progression of COVID-19, monitor seroconversion within general population, support vaccine development. majority currently available commercial serological assays only quantify antibody against individual antigens, limiting our understanding response. To overcome this, we have developed multiplex immunoassay (MultiCoV-Ab) including spike nucleocapsid proteins endemic human coronaviruses. Compared three broadly used in vitro diagnostic tests, MultiCoV-Ab achieves higher sensitivity specificity when analyzing well-characterized sample set infected uninfected individuals. We find high coronaviruses set, but no consistent cross-reactive IgG patterns SARS-CoV-2. Here show robust, high-content-enabled, antigen-saving assay suited both monitoring vaccination studies facilitating epidemiologic screenings towards pandemic